Objective  To observe the efficacy and safety of Jinqian Dantong granules in the treatment of chronic hepatitis B complicated with chronic cholecystitis with damp-heat syndrome of liver and gallbladder.

Methods  A randomized, double-blind experiment was conducted to divide patients with chronic hepatitis B combined with chronic cholecystitis into the Jinqian Dantong granules treatment group (the experimental group) and the Jinqian Dantong  simulant group (the control group). The pain scores, liver function, liver and gallbladder ultrasound and TCM syndrome scores of patients before and after treatment were observed.

Results  A total of 120 patients were included in the study, with 60 in each group. After treatment, the pain score of patients in the experimental group decreased significantly and was lower than that of the control group (P<0.05). The levels of alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyltranspetidase (GGT), total bilirubin (TBil), and hepatitis B virus surface antigen (HBsAg) of patients in the experimental group were significantly lower than those before treatment (P<0.05), there was no significant difference in the levels of ALT, AST, ALP, GGT, direct bilirubin (DBil), and hepatitis B e antigen (HBeAg) between the experimental group and the control group (P>0.05), and only the levels of TBil and HBsAg in the experimental group were lower than those in the control group (P<0.05). Three people in the experimental group switched from rough liver echoes to liver echoes without obvious abnormalities, and 43 people switched from rough gallbladder wall to gallbladder without obvious abnormalities. The traditional Chinese medicine syndrome scores in the experimental group decreased and were lower than those in the control group (P<0.05), and there were no obvious adverse reactions in both groups.

Conclusion  Jinqian Dantong granules can improve clinical symptoms such as liver and gallbladder damp-heat syndrome and gallbladder reflex zone pain in patients with chronic hepatitis B combined with chronic cholecystitis, reduce TBiL and HBsAg levels, and have a favorable safety profile.

1.中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6): 401-427. DOI: 10.3760/cma.j.issn.1674-2397. 2022.06.001.

2.贵州威门药业股份有限公司. 治疗胆石症的金钱胆通颗粒: 中国专利, ZL201610387142.7[P]. 2019-12-20.

3.付云舒. 金钱胆通颗粒对胆汁淤积大鼠肝脏保护作用及机制研究[D]. 广州: 南方医科大学, 2024. https://cdmd.cnki.com.cn/Article/CDMD-12121-1024071895.htm.

4.张倩, 韩竹箴, 谷丽华, 等. 连钱草的化学成分、药理作用研究进展及其质量标志物的预测分析[J]. 中国中药杂志, 2023, 48(8): 2041-2058. [Zhang Q, Han ZZ, Gu LH, et al. Research progress on chemical constituents and pharmacological effects of Glechomae herba and prediction of its Q-markers[J]. China Journal of Chinese Materia Medica, 2023, 48(8): 2041-2058.] DOI: 10.19540/j.cnki.cjcmm.20221115.201.

5.苏静, 王亚亚, 梁轩, 等. 金钱草的研究进展[J]. 华西药学杂志, 2024, 39(3): 357-363. [Su J, Wang YY, Liang X, et al. Research progress on Lysimachiae Herba[J]. West China Journal of Pharmaceutical Sciences, 2024, 39(3): 357-363.] DOI: 10.13375/j.cnki.wcjps.2024.03.024.

6.闫雅婕, 王亚亚, 梁轩, 等. 茵陈化学成分、药理作用及在肝胆疾病中的临床应用研究进展[J]. 中华中医药学刊, 2024, 42(11): 237-248. [Yan YJ, Wang YY, Liang X, et al. Research progress on chemical constituents, pharmacological effects and clinical application of Yinchen (Artemisiae scopariae herba) in hepatobiliary diseases[J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(11): 237-248.] DOI: 10.13193/j.issn.1673-7717.2024.11.046.

7.舒璟, 徐梓豪, 陈媛媛, 等. 虎杖苷的药理作用研究进展 [J]. 湖北科技学院学报(医学版), 2025, 39(1): 89-92. [Shu  J, Xu Z, Chen YY, et al. Research progress on pharmacological effects of polydatin[J]. Journal of Hubei University of Science and Technology(Medical Sciences), 2025, 39(1): 89-92.] DOI: 10.16751/j.cnki.2095-4646.2024060503.

8.中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

9.中华消化杂志编辑委员会, 中华医学会消化病学分会肝胆疾病协作组. 中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年)[J]. 中华消化杂志, 2019, 39(2): 73-79. DOI: 10.3760/cma.j.issn.0254-1432.2019.02.001.

10.张声生, 赵文霞. 胆囊炎中医诊疗专家共识意见(2017)[J].中国中西医结合消化杂志, 2017, 25(4): 241-246. [Zhang SS, Zhao WX. Consensus opinions of experts on TCM diagnosis and treatment of cholecystitis (2017)[J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 2017, 25(4): 241-246.] DOI: 10.3969/j.issn.1671-038X.2017.04.01.

11.李军祥, 陈誩, 梁健. 胆石症中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2): 132-138. [Li JX, Chen Y, Liang J. Consensus opinions on the diagnosis and treatment of integrated traditional Chinese and Western medicine in cholelithiasis (2017)[J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 2018, 26(2): 132-138.] DOI: 10.3969/j.issn.1671-038X.2018.02.04.

12.郑筱萸, 主编. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 85-86.

13.万丽, 赵晴, 陈军, 等. 疼痛评估量表应用的中国专家共识(2020版)[J]. 中华疼痛学杂志, 2020, 16(3): 177-187. [Wan L, Zhao Q, Chen J, et al. Chinese expert consensus on the application of the Pain Assessment Scale (2020 edition)[J]. Chinese Journal of Painology, 2020, 16(3): 177-187.] DOI: 10.3760/cma.j.cn101379-20190915-00075.

14.周威, 张赛, 刘智化, 等. 代谢因素与胆囊结石伴急性胆囊炎的相关性分析[J]. 肝胆外科杂志, 2024, 32(5): 381-385. [Zhou  W, Zhang S, Liu ZH, et al. Correlation analysis of metabolic factors with gallstones with acute cholecystitis[J]. Journal of Hepatobiliary Surgery, 2024, 32(5): 381-385.] DOI: 10.3969/j.issn.1006-4761. 2024.05.017.

15.Eva S, Milan J. New insights in bilirubin metabolism and their clinical implications[J]. World J Gastroenterol, 2013, 19(38): 6398-6407. DOI: 10.3748/wjg.v19.i38.6398.

16.Morgan AM, DePietro MD, Whorms SD, et al. Acalculous cholecystitis-an imaging and therapeutic update[J]. Abdom Radiol (NY), 2024: 1-11. DOI: 10.1007/S00261-024-04691-0.

17.张文俊, 李兆申, 谢渭芬, 等. 金钱胆通口服液治疗胆石症疗效研究[J]. 临床肝胆病杂志, 2003(4): 229-231. [Zhang WJ, Li  ZS, Xie WF, et al. Study on the efficacy of Qianbiliary oral solution in cholelithiasis[J]. Journal of Clinical Hepatology, 2003(4): 229-231.] DOI: 10.3969/j.issn.1001-5256. 2003.04.017.